匹多莫德辅治慢性阻塞性肺疾病稳定期疗效观察

目的观察应用匹多莫德辅助治疗慢性阻塞性肺疾病稳定期患者的临床疗效。方法93例慢性阻塞性肺疾病稳定期患者完全随机分为观察组（47例）与对照组（46例）。对照组给予支气管扩张剂、呼吸肌锻炼、氧疗、营养及对症支持等治疗。观察组在对照组基础上给予匹多莫德分散片0．8g／次，口服，1次／d。疗程均为8周。2组治疗前后均测定生活质量评分及慢性阻塞性肺疾病急性加重发作例数、住院治疗例数及住院时间，并进行比较。结果治疗后6个月，与对照组比较，观察组生活质量评分、慢性阻塞性肺疾病急性加重发作发生率、慢性阻塞性肺疾病急性加重需住院治疗发生率及住院时间均明显减少分别为（41．2±2．2）分比（49．3±2．1）分，28．3％（13／46）比84．4％（38／45），15．2％（7／46）比57．8％（26／45），（8．0±0．3）d比（14．0±0．4）d，均P〈0．05]。结论匹多莫德能有效提高患者机体免疫力，对减少慢性阻塞性肺疾病稳定期患者急性加重的发作有确切效果。

Effect of pidotimod on stable chronic obstructive pulmonary disease

Objective To observe the clinical curative effect of pidotimod on stable chronic obstructive pulmonary disease. Methods All 93 cases of stable chronic obstructive pulmonary disease patients were randomly divided into observation group（47 cases）and control group （46 cases）. The patients in control group were given bronchial diastolic agent, muscle training, nutrition support, family oxygen and symptomatic treatment. The patients in observation group were given pidotimod. Treatment lasted for eight weeks. Clinical symptom scores before and after treatment and chronic obstructive pulmonary disease in acute exacerbation period （AECOPD） cases were assayed. Results Six months after treatment, the StGeorg＇s respiration questionnaire scores, AECOPD attack rate, incidence and days of AECOPD in hospital in observation group were statistically less than those in control group （41.2 ± 2.2） scores vs （49.3 ± 2.1 ） scores, 28.3% （13/46） vs 84.4% （38/45）, 15.2% （7/46） vs 57.8% （ 26/45 ）, （ 8.0 ±0. 3 ） d vs （ 14.0 ± 0. 4 ） d, respectively, all P 〈 0. 05 ]. Conclusions Pidotimod can effectively enhance the immunity of the patients and reduce the cases of AECOPD in stable chronic ohstruetive pulmonary disease patients.